Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Open-label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of Inhaled LIQ861(Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients

NCT03399604 is registered in ClinicalTrials.gov with Liquidia Technologies, Inc. as lead sponsor.

NCT NCT03399604
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03399604 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Open-label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of Inhaled LIQ861(Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients
Lead sponsor
Liquidia Technologies, Inc.
Phase
Phase 3
Overall status
Completed
Start date
January 2, 2018
Completion date
November 25, 2019
Enrollment
121 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

primary pulmonary hypertension